January 16, 2024
A vaccine for Staphylococcus aureus, one of the most common bacterial infections, would be a game changer for public health. No vaccine candidates have succeeded in clinical trials, but nobody knows why. Researchers at UC San Diego may have figured it out.
July 3, 2012
Research suggests that patients with leukemia sometimes relapse because standard chemotherapy fails to kill the self-renewing leukemia initiating cells, often referred to as cancer stem cells. In such cancers, the cells lie dormant for a time, only to later begin cloning, resulting in a return and metastasis of the disease.…
December 15, 2015
Around this time every year, the flu virus infects up to one-fifth of the U.S. population and kills thousands of people, many of them elderly. A study published by Cell Press on Dec. 15 in Immunity now explains why the flu vaccine is less effective at protecting older individuals. More…
October 27, 2016
…study also shows that inhibiting CD98 with the therapeutic antibody IGN523 blocks AML growth in patient-derived cells and mouse models.
November 3, 2022
This season there are three prevalent respiratory viruses to be aware of—influenza, SARS-CoV-2 and respiratory syncytial virus (RSV), all of which are transmitted via aerosols.
February 18, 2015
…an immune-boosting cocktail suitable for use in humans, generated antibodies in mice that nearly eliminated mosquito infection by the malaria parasite. The method is the newest attempt to develop a vaccine that prevents transmission of the malaria parasite from host to mosquito.
August 27, 2020
…to complete. Q. Will antibody testing be available? A. While we have the capability, we will not be focusing on this as it does not contribute to our ability to control outbreaks. While most people do make antibodies after they become infected, most don’t have antibodies when they first become…
December 10, 2012
Biologists at UC San Diego have succeeded in genetically engineering algae to produce a complex and expensive human therapeutic drug used to treat cancer. Their achievement opens the door for making these and other “designer” proteins in larger quantities and much more cheaply than can now be made from mammalian…
November 21, 2011
A study using genetically modified zebrafish to visualize early events involved in development of human atherosclerosis describes an efficient model – one that the researchers say offers many applications for testing the potential effectiveness of new antioxidant and dietary therapies.
January 13, 2016
In the first clinical trial of its type, researchers at University of California, San Diego School of Medicine and the Alzheimer’s Disease Cooperative Study (ADCS), in collaboration with AC Immune, a biotechnology company based in Switzerland, will test the safety and tolerability of an immunotherapy vaccine that targets Alzheimer’s disease-like…
